One of the world's twenty largest drug companies will buy or license psilocybin (the active compound in magic mushrooms) from COMPASS Pathways or ATAI Life Sciences, the two main public companies developing it. These companies have successful clinical trial results that prove psilocybin works for depression and other conditions. Big pharma sees that their old product lines are running out of patent protection, so they're buying new breakthrough treatments. This matters because it means psilocybin could become a mainstream medicine.
Multiple concurrent RCTs demonstrating efficacy across indications constitute the de-risking signal large pharma acquirers require before committing capital. Patent cliffs on existing CNS franchises create M&A pressure. COMPASS and ATAI are the only publicly traded, patent-protected psilocybin platforms with Phase 2/3 data. Falsifiable: a named top-20 pharma company announces a definitive licensing agreement or acquisition of COMPASS or ATAI, confirmed by SEC filing or equivalent. Note: COMPASS and ATAI have been acquisition targets for 3+ years without a deal closing; base rate of non-occurrence is high, warranting confidence reduction.